Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 9 |
| List of Tables | 10 | 2 |
| List of Figures | 12 | 2 |
| Antibacterials - Introduction | 14 | 1 |
| Antibacterials - Overview | 15 | 17 |
| Bacterial Classification | 15 | 1 |
| Antimicrobial Spectrum | 15 | 1 |
| Bacterial Resistance | 16 | 1 |
| Antibacterial Classification | 16 | 1 |
| Cephalosporin Antibacterials | 16 | 1 |
| First Generation | 16 | 1 |
| Second Generation | 17 | 1 |
| Third Generation | 17 | 1 |
| Fourth Generation | 17 | 1 |
| Fifth Generation | 18 | 1 |
| Penicillin Antibacterials | 19 | 1 |
| Natural Penicillins | 19 | 1 |
| Penicillinase-Resistant Penicillins | 19 | 1 |
| Aminopenicillins | 19 | 1 |
| Extended Spectrum Penicillins | 20 | 1 |
| Quinolone Antibacterials | 20 | 1 |
| First Generation | 20 | 1 |
| Second Generation | 20 | 1 |
| Third Generation | 20 | 1 |
| Fourth Generation | 21 | 1 |
| Macrolide Antibacterials | 21 | 1 |
| Global Revenues for Antibacterials | 21 | 1 |
| Global Revenue and Forecast | 21 | 2 |
| Revenue Share by Indication | 23 | 1 |
| The US | 24 | 1 |
| Total Revenues | 24 | 1 |
| Europe (The UK, France, Germany, Spain, Italy) | 25 | 1 |
| Total Revenues | 25 | 2 |
| Japan | 27 | 1 |
| Total Revenues | 27 | 1 |
| Drivers and Barriers for the Antibacterials Market | 28 | 1 |
| Drivers for the Antibacterials Market | 28 | 1 |
| Increasing Prevalence of Bacterial Infections Leading to Increased Antibacterial Use will Drive the Market Growth | 28 | 1 |
| Increasing Need for Drugs that Tackle Gram-Negative Bacteria | 28 | 1 |
| Barriers for the Antibacterials Market | 28 | 1 |
| Antibacterial Prescription is not Always Required in Bacterial Infection | 28 | 1 |
| Drug Resistant Organisms | 28 | 1 |
| Regulatory Restrictions Make Antibacterial Development Especially Difficult | 29 | 1 |
| Diagnostic Tools are Slower than Required | 29 | 1 |
| Antimicrobial Stewardship Programs May Lead to Lower Prescription of Antibacterials | 29 | 1 |
| Lack of Prioritization Leads to a Loss of Resources and Expertise | 29 | 1 |
| The Research and Development Process Has a High Risk of Failure | 29 | 1 |
| Patent Expiry of Branded Products | 30 | 1 |
| Weak Pipelines | 30 | 1 |
| Government Campaigns that Aim to Reduce Antibacterial Use have Shown Effectiveness | 30 | 1 |
| Falling R&D Budgets and Low Rates of Approvals Affect the Industry as a Whole | 30 | 1 |
| Opportunities | 31 | 1 |
| Alliances with Academic and Research Institutions are the Way Forward for Big Pharma | 31 | 1 |
| Tuberculosis | 32 | 14 |
| Overview | 32 | 1 |
| Microbiology | 33 | 1 |
| Diagnosis | 33 | 1 |
| Treatment | 33 | 1 |
| Prevention | 34 | 1 |
| Tuberculosis Therapeutics Market Size | 35 | 1 |
| Total Revenue | 35 | 3 |
| Average Annual Cost of Treatment (ACT) | 38 | 1 |
| Treatment Usage Patterns | 39 | 1 |
| Diseased Population | 39 | 3 |
| Drivers and Barriers for the Tuberculosis Therapeutics Market | 42 | 1 |
| Drivers for the Tuberculosis Therapeutics Market | 42 | 1 |
| New Diagnostic Techniques will Improve Detection and Treatment Rates | 42 | 1 |
| Increase in Aged Population Increases Tuberculosis Prevalence | 42 | 1 |
| Increase in Tuberculosis Cases in Europe | 42 | 1 |
| Co-infection with HIV is Driving the Incidence of Tuberculosis | 42 | 1 |
| Barriers to the Tuberculosis Therapeutics Market | 43 | 1 |
| Poor Compliance Rates | 43 | 1 |
| Stigma of Tuberculosis Decreases Treatment-Seeking Population | 43 | 1 |
| Vaccines | 43 | 1 |
| Increasing Prevalence of MDR-TB May Present Future Problems | 43 | 1 |
| Product Profile of the Major Marketed Products in the Tuberculosis Market | 43 | 1 |
| Isoniazid (Isonicotinylhydrazine, INH) | 43 | 1 |
| Overview | 43 | 1 |
| Clinical Trials | 43 | 1 |
| Pricing | 44 | 1 |
| Rifampin (RIF) | 44 | 1 |
| Overview | 44 | 1 |
| Clinical Trials | 44 | 1 |
| Dosage and Pricing | 44 | 1 |
| Pyrazinamide (PZA) | 44 | 1 |
| Overview | 44 | 1 |
| Dosage and Pricing | 44 | 1 |
| Ethambutol (EMB) | 45 | 1 |
| Overview | 45 | 1 |
| Dosage and Pricing | 45 | 1 |
| Pneumonia | 46 | 16 |
| Overview | 46 | 1 |
| Microbiology | 46 | 1 |
| Diagnosis | 46 | 1 |
| Treatment | 47 | 1 |
| Prevention | 48 | 1 |
| Pneumonia Therapeutics Market Size | 49 | 1 |
| Total Revenue | 49 | 3 |
| Annual Cost of Treatment (ACT) | 52 | 1 |
| Treatment Usage Patterns | 53 | 1 |
| Diseased Population | 54 | 1 |
| Treatment Seeking Population | 54 | 1 |
| Diagnosed Population | 54 | 1 |
| Prescription Population | 54 | 1 |
| Drivers and Barriers to the Pneumonia Therapeutics Market | 55 | 1 |
| Drivers for the Pneumonia Therapeutics Market | 55 | 1 |
| Increase in Diseased Population | 55 | 1 |
| Multiple Causes of Pneumonia Make it Difficult to Control, Providing a Good Patient Population | 55 | 1 |
| Barriers to the Pneumonia Antibacterials Market | 55 | 1 |
| Multi-Drug Resistant Organisms Reduce the Efficacy of Antibacterials | 55 | 1 |
| Cost of Therapy is Low and Patent Expiries are Expected to Compound this Situation | 55 | 1 |
| Stringent Regulatory Hurdles and Failures of Drug Approvals Discourage Development in the Pneumonia Therapeutics Market | 55 | 1 |
| Weak Pipeline Reduces Market Potential | 56 | 1 |
| Increased Awareness of Necessary Procedures in Hospitals to Prevent the Spread of Nosocomial Pneumonia | 56 | 1 |
| Problems with the Classification and Treatment of Pneumonia | 56 | 1 |
| Increasing Focus on the Emerging Markets | 57 | 1 |
| Product Profile of the Major Marketed Products in the Pneumonia Antibacterials Market | 57 | 1 |
| Zyvox (linezolid) | 57 | 1 |
| Overview | 57 | 1 |
| Efficacy | 57 | 1 |
| Safety | 57 | 1 |
| Dosage and Pricing | 57 | 1 |
| Zosyn (piperacillin and tazobactum) | 58 | 1 |
| Overview | 58 | 1 |
| Clinical Trials | 58 | 1 |
| Dosage and Pricing | 58 | 1 |
| Levaquin (levofloxacin) | 58 | 1 |
| Overview | 58 | 1 |
| Clinical Trials | 58 | 1 |
| Dosage and Pricing | 59 | 1 |
| Avelox (moxifloxacin) | 59 | 1 |
| Overview | 59 | 1 |
| Clinical Trials | 59 | 1 |
| Dosage and Pricing | 59 | 1 |
| Omnicef (cefnidir) | 59 | 1 |
| Overview | 59 | 1 |
| Clinical Trials | 60 | 1 |
| Dosage and Pricing | 60 | 1 |
| Tygacil (tigecycline) | 60 | 1 |
| Overview | 60 | 1 |
| Clinical Trials | 60 | 1 |
| Dosage and Pricing | 60 | 1 |
| Doribax (doripenem) | 61 | 1 |
| Overview | 61 | 1 |
| Clinical Trials | 61 | 1 |
| Dosage and Pricing | 61 | 1 |
| Urinary Tract Infections | 62 | 14 |
| Overview | 62 | 1 |
| Cystitis | 62 | 1 |
| Urethritis | 62 | 1 |
| Pyelonephritis | 62 | 1 |
| Microbiology | 62 | 1 |
| Diagnosis | 62 | 1 |
| Urinalysis | 62 | 1 |
| Urine Culture | 62 | 1 |
| Treatment | 63 | 1 |
| Treatment for Uncomplicated UTIs | 63 | 1 |
| Prevention | 64 | 1 |
| Urinary Tract Infection Therapeutics Market Size | 64 | 1 |
| Total Revenue | 64 | 3 |
| Annual Cost of Treatment (ACT) | 67 | 1 |
| Treatment Usage Patterns | 68 | 1 |
| Diseased Population | 69 | 1 |
| Treatment Seeking Population | 69 | 1 |
| Diagnosed Population | 69 | 1 |
| Prescription Population | 69 | 1 |
| Drivers and Barriers for the Urinary Tract Infection Therapeutics Market | 70 | 1 |
| Drivers for the UTI Therapeutics Market | 70 | 1 |
| High Prevalence of the Disease | 70 | 1 |
| The Aging Population and their Co-Morbidities Increases the Patient Volume | 70 | 1 |
| Barriers for the UTI Therapeutics Market | 70 | 1 |
| Unmet Need for the UTI Treatment Market is Low | 70 | 1 |
| Generic Dominance in the Market Decreases Revenues | 70 | 1 |
| Increasing Resistance to Antibacterials Reduces their Ability to Treat UTIs | 71 | 1 |
| Product Profile of the Major Marketed Products in the Urinary Tract Infection Market | 71 | 1 |
| Doribax (doripenem) | 71 | 1 |
| Overview | 71 | 1 |
| Clinical Trials | 71 | 1 |
| Dosage and Pricing | 71 | 1 |
| Ciprofloxacin | 72 | 1 |
| Overview | 72 | 1 |
| Clinical Trials | 72 | 1 |
| Dosage and Pricing | 72 | 1 |
| Levaquin (levafloxacin) | 73 | 1 |
| Overview | 73 | 1 |
| Clinical Trials | 73 | 1 |
| Dosage and Pricing | 73 | 1 |
| Monurol (fosfomycin tromethamine) | 74 | 1 |
| Overview | 74 | 1 |
| Efficacy | 74 | 1 |
| Dosage and Pricing | 74 | 1 |
| Macrobid (nitrofurantoin) | 74 | 1 |
| Overview | 74 | 1 |
| Efficacy | 75 | 1 |
| Dosage and Pricing | 75 | 1 |
| Atypical Bronchitis | 76 | 8 |
| Overview | 76 | 1 |
| Microbiology | 76 | 1 |
| Diagnosis | 76 | 1 |
| Treatment | 76 | 1 |
| Prevention | 76 | 1 |
| Atypical Bronchitis Therapeutics Market Size | 77 | 1 |
| Total Revenue | 77 | 2 |
| Annual Cost of Treatment (ACT) | 79 | 1 |
| Treatment Usage Patterns | 80 | 1 |
| Diseased Population | 81 | 1 |
| Treatment Seeking Population | 81 | 1 |
| Diagnosed Population | 81 | 1 |
| Prescription Population | 81 | 1 |
| Drivers and Barriers for the Atypical Bronchitis Therapeutics Market | 82 | 1 |
| Drivers for the Atypical Bronchitis Therapeutics Market | 82 | 1 |
| Worsening Environmental Conditions Coupled with Population Growth Increase the Prevalence of Bronchitis | 82 | 1 |
| Association with Smoking | 82 | 1 |
| Barriers for the Atypical Bronchitis Therapeutics Market | 82 | 1 |
| The Disease is Generally Mild and Patients do not Require Antibiotics | 82 | 1 |
| Antimicrobials Advised Against During Acute Bronchitis | 82 | 1 |
| Weak Pipeline due to Low Unmet Need | 82 | 1 |
| Marketed Products | 83 | 1 |
| Tonsillitis | 84 | 8 |
| Overview | 84 | 1 |
| Microbiology | 84 | 1 |
| Diagnosis | 84 | 1 |
| Clinical Examination | 84 | 1 |
| Culture and Sensitivity Test | 84 | 1 |
| Treatment | 84 | 1 |
| Prevention | 85 | 1 |
| Tonsillitis Therapeutics Market Size | 85 | 1 |
| Total Revenue | 85 | 2 |
| Annual Cost of Treatment (ACT) | 87 | 1 |
| Treatment Usage Patterns | 88 | 1 |
| Diseased Population | 89 | 1 |
| Treatment Seeking Population | 89 | 1 |
| Diagnosed Population | 89 | 1 |
| Prescription Population | 89 | 1 |
| Drivers and Barriers for the Tonsillitis Therapeutics Market | 90 | 1 |
| Drivers for the Tonsillitis Therapeutics Market | 90 | 1 |
| Other Therapeutics and Surgery Used in the Treatment of Tonsillitis are More Expensive and Encourage Generic Antibiotic Use | 90 | 1 |
| Diagnosis of Tonsillitis is Easy | 90 | 1 |
| Barriers for the Tonsillitis Therapeutics Market | 90 | 1 |
| Weak Pipelines Hold Low Promise for the Future | 90 | 1 |
| Generic Antibacterials are Commonly Used | 90 | 1 |
| Symptomatic Therapies are Often Used by Patients to Reduce Pain, and Consequently Medical Therapy is Not Sought | 90 | 1 |
| Marketed Products | 91 | 1 |
| Spectracef | 91 | 1 |
| Safety | 91 | 1 |
| Dosage | 91 | 1 |
| Sinusitis | 92 | 10 |
| Overview | 92 | 1 |
| Frontal Sinusitis (located behind the forehead) | 92 | 1 |
| Ethmoid Sinusitis (behind the bridge of the nose) | 92 | 1 |
